KCNQ Potassium Channel Modulators Selective Subtype Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current KCNQ openers, such as flupirtine and retigabine, used for treating conditions like pain, epilepsy, and anxiety, exhibit adverse effects like asthenia, ataxia, insomnia, and sedation, necessitating the development of KCNQ openers that selectively activate specific subtypes to reduce side effects.
Innovation Solution
Compounds of formula (I) or their pharmaceutically acceptable salts/solvates, which are modulators of KCNQ potassium channels, are designed to selectively activate KCNQ channels, thereby treating conditions like pain, epilepsy, and anxiety with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current KCNQ openers (flupirtine and retigabine) are used to treat pain, epilepsy, and anxiety, then therapeutic efficacy is achieved, but adverse effects (asthenia, ataxia, insomnia, sedation) occur
Solution Approach 1:
The patent segments the KCNQ channel family into distinct subtypes (KCNQ2, KCNQ3, KCNQ4, KCNQ5) and develops compounds that selectively target specific subtypes rather than activating all subtypes non-specifically. This segmentation approach allows the invention to achieve therapeutic efficacy for conditions like pain, epilepsy, and anxiety while minimizing adverse effects by avoiding activation of subtypes not involved in the therapeutic response.
Solution Approach 2:
The patent applies local quality by designing compounds with specific molecular structures (formula I with various substituents R1a, R1b, R2, T, G1) that confer selectivity for particular KCNQ subtypes. Different substituent patterns create localized interactions with specific subtype binding sites, enabling the compound to activate only the desired subtype(s) responsible for therapeutic effects while leaving other subtypes unaffected.
2Object-affected harmful factors
If KCNQ openers are developed to reduce side effects through subtype selectivity, then adverse effects are minimized, but drug development complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular structure parameters (substituents R1a, R1b, R2, T, G1, and their positions) to optimize subtype selectivity. By changing these chemical parameters, the invention achieves desired selectivity profiles for specific KCNQ subtypes while managing development complexity through structure-activity relationship (SAR) analysis and iterative optimization of these defined parameters.
Data Source
AI summary
Disclosed herein are KCNQ potassium channels modulators of formula (I)wherein G1, R2, R1a, R1b, X, X1, X2, X3, Rx, J, k, n, q, and t are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.